- Global Pharma News & Resources

Chronic Stable Angina - Pipeline Insight, 2019 -

The "Chronic Stable Angina - Pipeline Insight, 2019" drug pipelines has been added to's offering.

This report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Chronic Stable Angina development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Chronic Stable Angina

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Chronic Stable Angina

The report assesses the active Chronic Stable Angina pipeline products by developmental stage, product type, molecule type, and administration route.

Companies Featured

  • AstraZeneca
  • Pfizer
  • Sinphar Pharmaceutical Co. Ltd.
  • Bayer
  • AstraZeneca
  • Amgen
  • Chong Kun Dang Pharmaceutical
  • Euro CTO Club

Topics Covered

1. Report Introduction

2. Chronic Stable Angina Overview

3. Pipeline Therapeutics

4. Comparative Analysis

5. Products in Clinical Stage

6. Products in Pre-Clinical & Discovery Stage

7. Therapeutic Assessment

8. Inactive Products

For more information about this drug pipelines report visit

View source version on

Editor Details

Last Updated: 22-Jan-2019